Cost–Utility Analysis of Control-IQ Technology Relative to Conventional Insulin Therapy in Adults with Type 1 Diabetes
Main finding · QALYs, total costs and ICURResult — go to the resultICUR €21,111 per QALYAuthors' conclusion
Control-IQ provides clinical benefits relative to MDI and standard insulin pump therapy plus CGM in adults with type 1 diabetes in Belgium and appears to be cost-effective in this setting, considering commonly used thresholds.
Study context
- Population
- Adults with T1D, Belgium (payer perspective)
- Exposure
- Control-IQ vs MDI and standard insulin pump therapy plus CGM
- Outcome
- Quality-adjusted life years (QALYs) and incremental cost-utility ratios (ICURs)
- Follow-up
- Lifetime
Methodological detailslifetime horizon, IQVIA CORE Diabetes Model, payer perspective, inputs from real-world multicentre prospective INRANGE study
- Lifetime horizon
- IQVIA CORE Diabetes Model
- Payer perspective
- Inputs from real-world multicentre prospective INRANGE study
Main finding
QALYs, total costs and ICUR
ICUR
€21,111 per QALY
By group
As reported in the abstract
Observational data: associations, not effects.
Further findings
Scenario analysis: MDI + CGM as sole comparator · lifetime
- ICUR
- €41,701/QALY
- Scenario analyses confirmed robustness
Scenario analysis: reduced HbA1c efficacy · lifetime
- ICUR
- €25,967/QALY
- Scenario analyses confirmed robustness
Scenario analysis: 20-year time horizon
- ICUR
- €30,183/QALY
- Scenario analyses confirmed robustness
Original publication
Cost–Utility Analysis of Control-IQ Technology Relative to Conventional Insulin Therapy in Adults with Type 1 Diabetes. Diabetes Technol Ther. Published 22 December 2025. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →